Malaria caused by Plasmodium vivax is responsible for substantial morbidity in developing countries, producing 75-90 million cases of clinical malaria each year. Increasing prevalence of drug resistance in P. vivax, its global distribution and the appearance of more virulent forms of vivax malaria emphasizes the need for development of vaccines against this disease. Vivax malaria severely incapacitates infected persons, causing severe anemia, especially in young children, and an increased risk of low-birth-weight babies in pregnant women. Immunity to erythrocyte invasion ligands plays the critical role in controlling the blood-stage infection of P. vivax, since this malaria parasite does not sequester. Only persons that express the Duffy blood group antigen are infected with blood-stage P. vivax. Recognition of this human erythrocyte surface receptor is dependent upon the Duffy binding protein (DBP) cysteine-rich ligand domain, also known as region II or Duffy binding-like (DBL) domain. This essential interaction is a critical weakness in the parasite's life cycle. The major obstacle for developing this antigen as an effective vaccine is its high degree of polymorphism that makes ineffective the normal immune response following infection. Understanding the DBP-DARC interaction provides a model for all erythrocytes binding domains for Plasmodium-erythrocyte interaction.
The specific aims will define the immunological and functional properties of the DBP ligand domain and identify functionally conserved determinants of the receptor-binding site that are able to induce a broadly inhibitory antibody response capable of inhibiting blood-stage development of Plasmodium vivax.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
MO, Annie X Y
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of South Florida
Other Health Professions
Schools of Public Health
United States
Zip Code
Armistead, Jennifer S; Adams, John H (2018) Advancing Research Models and Technologies to Overcome Biological Barriers to Plasmodium vivax Control. Trends Parasitol 34:114-126
Roth, Alison; Maher, Steven P; Conway, Amy J et al. (2018) A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat Commun 9:1837
Adams, John H; Mueller, Ivo (2017) The Biology of Plasmodium vivax. Cold Spring Harb Perspect Med 7:
Ovchynnikova, Elina; Aglialoro, Francesca; Bentlage, Arthur E H et al. (2017) DARC extracellular domain remodeling in maturating reticulocytes explains Plasmodium vivax tropism. Blood 130:1441-1444
Ntumngia, Francis B; Pires, Camilla V; Barnes, Samantha J et al. (2017) An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies. Sci Rep 7:13779
Salinas, Nichole D; Tolia, Niraj H (2016) Red cell receptors as access points for malaria infection. Curr Opin Hematol 23:215-23
Chen, Edwin; Salinas, Nichole D; Huang, Yining et al. (2016) Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein. Proc Natl Acad Sci U S A 113:6277-82
Ntumngia, Francis B; Thomson-Luque, Richard; Torres, Letícia de Menezes et al. (2016) A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive Reticulocytes. MBio 7:
Shaw-Saliba, Kathryn; Thomson-Luque, Richard; Obaldía 3rd, Nicanor et al. (2016) Insights into an Optimization of Plasmodium vivax Sal-1 In Vitro Culture: The Aotus Primate Model. PLoS Negl Trop Dis 10:e0004870
Nicolete, Vanessa C; Frischmann, Sarah; Barbosa, Susana et al. (2016) Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. J Infect Dis 214:1539-1546

Showing the most recent 10 out of 38 publications